Bax Inhibitor-1 Is Overexpressed in Prostate Cancer and Its Specific Down-Regulation by RNA Interference Leads to Cell Death in Human Prostate Carcinoma Cells

Michal Grzmil,* Paul Thelen,† Bernhard Hemmerlein,‡ Stefan Schweyer,‡ Silke Voigt,* Dina Mury,* and Peter Burfeind*

From the Institute of Human Genetics,* Göttingen, and the Departments of Urology† and Pathology,‡ University of Göttingen, Göttingen, Germany

To analyze differential gene expression of putative prostate tumor markers we compared the expression levels of more than 400 cancer-related genes using the cDNA array technique in a set of capsule-invasive prostate tumor and matched normal prostate tissue. The overexpression of Bax inhibitor-1 (BI-1) in prostate carcinoma and prostate cancer cell lines was confirmed by using Northern blot and Western blot analyses. Quantitative real-time reverse transcription-polymerase chain reaction (RT-PCR) on intact RNAs from 17 paired laser-captured microdissected epithelial tissue samples confirmed up-regulated BI-1 expression in 11 of 17 prostate tumors. In addition, it was demonstrated that BI-1 expression is down-regulated in stromal cells as compared to matched normal epithelial cells of the prostate. In situ hybridization experiments on prostate sections also revealed that BI-1 expression is mainly restricted to epithelial cells. Furthermore, quantitative RT-PCR on RNAs derived from five benign prostate hyperplasia (BPH) samples showed no significant difference in BI-1 expression as compared to normal epithelial prostate tissue. To determine the function of BI-1 in vitro, human PC-3, LNCaP, and DU-145 prostate carcinoma cells were transfected with small interfering double-strand RNA (siRNA) oligonucleotides against the BI-1 gene leading to a specific down-regulation of BI-1 expression. Furthermore, transfection of PC-3, LNCaP, and DU-145 cells with BI-1 sequence-specific siRNAs caused a significant increase in spontaneous apoptosis in all cell lines. Taken together, our results indicate that the human BI-1 gene contains the potential to serve as a prostate cancer expression marker and as a potential target for developing therapeutic strategies for prostate cancer. (Am J Pathol 2003, 163:543–552)

Prostate cancer is the most frequently diagnosed solid tumor in men, and the second leading cause of cancer death in males from western countries.1 One of the key issues in prostate cancer research is to develop molecular markers that can effectively detect and distinguish the progression and malignancy of prostate tumors as well as provide insights into prostate tumor development or behavior. Progress in identifying such markers has been markedly accelerated by recent advances in molecular biology technologies, such as cDNA array and microarray techniques, which enabled analyzing the expression of thousands of genes in a single experiment and hold great promise for a better understanding of the molecular genetics and biology of prostate cancers.2,3 Also, the recent development of laser-capture microdissection (LCM), a technique that allows for the reliable and accurate procurement of cells from specific microscopic regions of tissue sections under direct visualization, now affords the opportunity to perform molecular genetic analysis of pure populations of prostate cancer cells in their native tissue environment.4

Compelling evidence suggests that the tumorigenic growth of the prostate depends on the evasion of normal homeostatic control mechanisms, because of an increase in cell proliferation and a decrease in apoptotic death.5,6 Thus, enhancing the apoptotic process emerges as a significant therapeutic target for the effective elimination of both androgen-dependent and androgen-independent prostate cancer cells.7 Recently, reported adenovirus-mediated Bax overexpression induced apoptosis of LNCaP, PC-3, and DU-145 growing in vitro and in vivo.8 However, the pro-apoptotic protein Bax seems to be expressed in all prostate cancers evaluated but the expression of several anti-apoptotic members of the bcl-2 gene family increases during progres-

Supported by a grant from the Deutsche Forschungsgemeinschaft (BU-992/2–2 to P.B.), by the Forschungsförderungsprogramm from the Medical Faculty, University of Göttingen (to P.B.), and by the European Union (E)UROESTROGEN(E)S contract QLK6-CT-200–00565 (to P.T.)

M.G. and P.T. contributed equally to this work.

Address reprint requests to Dr. Peter Burfeind, Institute of Human Genetics, University of Göttingen, Heinrich-Düker Weg 12, 37073 Göttingen, Germany. E-mail: pburfei@gwdg.de.

543
sion of prostate cancers. Therefore, it is important to unravel the mechanisms protecting prostate cancer cells from undergoing apoptosis and to identify new therapeutic targets and to develop new treatments. Recently, the novel anti-apoptotic protein Bax inhibitor-1 (BI-1), formerly known as testicular enhanced gene transcript (TEGR), was shown to represent a new type of regulator of cell death pathways controlled by Bcl-2 and Bax. It was demonstrated that BI-1 can interact with Bcl-2 and Bcl-X, but not Bax and Bad, and when overexpressed in mammalian cells, BI-1 suppressed apoptosis induced by Bax, etoposide, staurosporine, and growth factor deprivation, but not by Fas (CD95).

In this report, we identified BI-1 overexpression in prostate carcinoma by using the cDNA array technique. These findings were confirmed on RNAs from LCM-derived prostate tumor tissue samples in 12 of 18 patients using either Northern blot or real-time RT-PCR analyses. Moreover, both quantitative RT-PCR and in situ hybridization experiments demonstrated up-regulated BI-1 expression in epithelial cells as compared to stromal cells. In addition, no significant difference was observed in BI-1 expression between normal prostate cells of epithelial origin and from cells derived from BPH samples. Furthermore, we demonstrate that down-regulation of BI-1 expression via sequence-specific siRNA against the human BI-1 gene leads to a significant increase of PC-3, LNCaP, and DU-145 prostate carcinoma cell death. These results indicate an important role for BI-1 in cellular homeostasis of prostate carcinoma and provide a basis for targeting BI-1 as a potential treatment for prostate cancer.

Materials and Methods

Atlas Select Human Tumor Arrays

Total RNA (50 μg) from paired prostate and prostate carcinoma tissue, respectively, was isolated with the RNeasy Mini Kit (Qiagen GmbH, Hilden, Germany) from a 68-year-old patient (Gleason score 5, tumor stage pT3aN0). Total RNA was treated with RNase-free DNase I (BD Biosciences Clontech, Heidelberg, Germany) and checked on a denaturing agarose gel. The 32P-cDNA probes were prepared using the Atlas Pure Total RNA Labeling system (Clontech) according to the user manual and were hybridized side-by-side to two identical Atlas Select Human Tumor Arrays (BD Biosciences Clontech). The Atlas Select Human Tumor Array includes cDNAs for 437 differentially-expressed human genes, 32 control cancer genes, nine housekeeping control genes, and negative controls immobilized on a nylon membrane. The differentially expressed genes included on this array were shown to be up- or down-regulated in human tumors using Clontech PCR-Select cDNA Subtraction in conjunction with an array-based screening method. After overnight hybridization and a high-stringency wash (according to the procedure described in the Atlas Array user manual), arrays were scanned after a 3-day exposure by using a Molecular Imager FX (Bio-Rad GmbH, Munich, Germany) and analyzed by using the Quantity One software (Bio-Rad).

Laser Capture Microdissection and Real-Time RT-PCR Analysis

Tissue specimens from benign prostate hyperplasia (BPH) and radical prostatectomy specimens of patients suffering from prostate cancer were freshly obtained from the urological operation theater of the university hospital. Specimens from radical prostatectomies were immediately cut in 3-mm-thick transversal slices. One slice suspected to contain carcinoma tissue was soaked in RNAlater reagent (Ambion Europe Ltd., Cambridge, UK). The complete transverse section was mapped and cut into small tissue blocks, which were further stored in RNAlater. The rest of the prostate, especially adjacent prostate slices, were fixed in formalin and embedded in paraffin for standard histological examination. Staging was performed according to the UICC classification. Tumors were graded using the Gleason score. According to the adjacent paraffin sections RNAlater-preserved tissue was selected. Cryostat sections were hematoxylin-eosin stained and the tissue was morphologically characterized. Tumor-containing tissue blocks and tumor-free prostate tissue of the same case were selected for further analysis. Five-μm-thick cryostat sections were mounted on slides coated with a 1.35-μm-thick polyethylene naphthalene membrane (P.A.L.M. Microlaser Technologies, Bernried, Germany). Subsequently, sections were washed for 2 hours in 70% ethanol/DEPC (diethyl pyrocarbonate)-treated water followed by staining with Harris hemalaun. Color was developed by incubation with DEPC-treated tap water for 2 hours. Lastly, slides were dipped in pure ethanol and xylol, air-dried, and subjected to contact-free laser microdissection (P.A.L.M.) at a magnification of ×200. The dissected normal epithelia and carcinoma epithelia were automatically transferred into lids of PCR vials and collected in RLT buffer (Qiagen) substituted with β-mercaptoethanol. LCM-derived tissue samples from Stromal cells, from matched normal epithelial cells and from BPH were isolated and treated as described above. Total cellular RNA from LCM samples was extracted with the RNeasy Mini Kit (Qiagen), RNA integrity and quantity was assessed using the Agilent Bioanalyzer 2100 with the RNA Pico LabChip Kit (Agilent Technologies, Waldbronn, Germany). Additional controls were performed by analyzing unstained tissue sections and the remaining tissue after microdissection. Reverse transcription with random hexamer primers was performed with the Sensiscript RT Kit (Qiagen). Quantification of BI-1 and β-actin expression was performed on an iCycler iQ real-time detection system (Bio-Rad, Hercules, CA) using the HotStar TaqDNA Polymerase Kit (Qiagen). The 20-μl reaction from the kit was supplemented with 2 μl cDNA, 0.6 μmol/L gene-specific primers, and 0.2 μmol/L dual-labeled fluorescent probes for BI-1 and β-actin with different fluorophores FAM and Texas Red allowing for duplex PCR. Primers and probes (Operon; Qiagen) were designed using the Primer3 online primer
design program (http://www-genome.wi.mit.edu/genome_software/other/primer3.html). Primers used for quantitative RT-PCR were: BI-1 forward primer, 5'-ACGGACTCTG-GAACATGAA-3'; BI-1 reverse primer, 5'-AGCGGCCAC-AAACATACAA-3'; BI-1 probe, 5'-Fam-ATATAACCCGT-CAACGAGGACCAC-Tamra-3'; β-actin forward primer, 5'-TCACCCACACTGTGCCCATCTACA; β-actin reverse primer, CCTAACGTTACTCCAGACGAGC-3'; β-actin probe, 5'-Texas Red-ATGCCCTCCCCCATGCGACGT-TCG-3'. A standard curve for quantitative PCR was generated with the same reaction set-up using BI-1 and β-actin standard cRNA (0.001 to 1000 attomoles) instead of total cellular RNA. Acquisition of fluorescence signals was monitored on the iCycler and terminated when all reactions reached an amplification plateau while a template-free control stayed at a basal level. Data analysis was performed with the iCycler iQ real-time detection system software (Bio-Rad). To verify that only specific PCR products evoked fluorescence signals, PCR products were run on 2% agarose gels and were analyzed using the E.A.S.Y. Win32 software (Herolab, Wiesloch, Germany). BI-1 mRNA expression was normalized to β-actin mRNA expression to compensate for different sample capacities. The ratio of BI-1 expression is given as factor up-regulation in prostate tumor, 8 kDa (Mat-8) gene (Mat-8 sense RNA: 5'-CGUACGCGGAAUACUCGATT-3'; luc antisense RNA: 5'-UGCAAUGAUUCUCGCUAGCTT-3') or against the human Mammary tumor, 8 kDa (Mat-8 sense RNA: 5'-CGUACGCGGAAUACUCGATT-3'; luc antisense RNA: 5'-GUCAUAGUGAAAGGCAGCUG-3'). At different time points after transfection (24 hours, 36 hours, and 45 hours), living cells attached to the bottom and cells floating in the medium were collected and used in the following experiments.

**Cell Culture and Transfection**

PC-3, LNCaP and DU-145 cells were grown in RPMI 1640 medium (PAN-Systems GmbH, Nürnberg, Germany) containing 15% fetal bovine serum (FBS) and 1% penicillin/streptomycin solution (PAN). The cells were cultured at 37°C in a humidified incubator with 5% CO₂ and grown to 10% to 20% confluence in 12-well plates before transfection with RNA oligonucleotides.

Transfection of PC-3, LNCaP, and DU-145 cells was accomplished using Oligofectamine Reagent (Invitrogen GmbH, Karlsruhe, Germany) according to the supplier’s instructions with either BI-1 gene-specific siRNA duplex or with single-strand sense and antisense RNA oligonucleotides (IBA GmbH, Goettingen, Germany) (BI-1 sense RNA: 5’-CCCCGUCAACCGCAGGACGACdTdT-3’; BI-1 antisense RNA: 5’-UGCUCGUGCGUUAGCCGGG GdGdTdT-3’) at a concentration of 0.66 μg per 0.5 ml of transfection medium (150 nmol/L). The target region is located 57 nucleotides downstream of the start codon ATG of the human BI-1 gene (GenBank Accession No. X75861). As further controls PC-3 cells were transfected with either siRNA duplex oligonucleotides against the firefly luciferase gene (luc sense RNA: 5’-CGUACGCGGAAUACUCGATT-3’; luc antisense RNA: 5’-UGCAAUGAUUCUCGCGUAGCTT-3’) or against the human Mammary tumor, 8 kDa (Mat-8 sense RNA: 5’- CGUACGCGGAAUACUCGATT-3’; Mat-8 antisense RNA: 5’-GUCAUAGUGAAAGGCAGCUG-3’). At different time points after transfection (24 hours, 36 hours, and 45 hours), living cells attached to the bottom and cells floating in the medium were collected and used in the following experiments.

LNCaP cells were maintained in phenol red-free DMEM (Invitrogen) supplemented with 10% fetal calf serum (FCS; PAA, Coelbe, Germany), 2% glutamine, 1% sodium-pyruvate, and 1% penicillin-streptomycin. Cells were plated in 6-well plates at a density of 10⁶ cells per well for dihydrotestosterone treatment (final concentration 10⁻⁸ M dihydrotestosterone). Cells were harvested after dihydrotestosterone treatment at different time points (1 hour, 2 hours, 4 hours, and 24 hours) by trypsinization and washed with PBS (BioWhittaker, Verviers, Belgium) before RNA extraction and real-time RT-PCR. Cell viability under hormone treatments was measured by using an MTT test. All chemicals were purchased from a Aldrich (Taufkirchen, Germany) unless stated otherwise.

**Northern Blot Analysis**

Total RNA was isolated from tissue samples, PC-3 cells, LNCaP cells, and DU-145 cells with the RNeasy Mini Kit (Qiagen) according to the manufacturer’s instructions, separated on a denaturing agarose gel and transferred to a Hybond-N nylon membrane (Amersham Pharmacia Biotech, Buckinghamshire, UK). The cDNA probes for human β-actin (IMAGp998L23787) and human BI-1 (IMAGp998B10404) were purchased from Deutsches Ressourcenzentrum für Genomforschung GmbH (RZPD, AJP August 2003, Vol. 163, No. 2
Berlin, Germany). The probes were labeled with [32P]dCTP using the rediprime II labeling kit (Amersham) and hybridized to the membrane in Rapid-hyb buffer (Amersham) together with 100 μg/ml denatured salmon sperm DNA at 65°C for 16 hours. The filters were washed at room temperature for 15 minutes in 2X SSC followed by 5 to 15 minutes in 0.5X SSC and 0.5% SDS (w/v) at 65°C. The hybridization signals were quantified with a Molecular Imager FX by using the Quantity One software (both from Bio-Rad).

Western Blot Analysis

The goat polyclonal antibody against human BI-1 (A-18) was purchased from Santa Cruz Biotechnology Inc. (Heidelberg, Germany), and the mouse monoclonal antibody against α-tubulin was obtained from a–Aldrich. Parental and transfected PC-3, LNCaP, and DU-145 cells were incubated in the appropriate medium as described above and whole-cell lysates were prepared from lysis buffer containing 50 mmol/L NaCl, 10 mmol/L ethylenediaminetetraacetic acid, 50 mmol/L Tris-HCl pH 7.6, 1% Triton X-100, 1 μg/ml leupeptin, 1 μg/ml aprotinin, and 1 μg/ml phenylmethylsulfonyl fluoride. Fifty μg of total cell lysates were boiled and denatured in sample buffer containing SDS and dithiothreitol (DTT; Invitrogen) followed by gel electrophoresis using the NuPage 10% Bis-Tris pre-cast gel (Invitrogen) in MES buffer (Invitrogen). The proteins were electrotransferred to nitrocellulose membrane (Amersham). The resulting protein-bound membrane was blotted with selected antibodies as described above and visualized using 5-bromo-4-chloro-3-indolyl phosphate/nitroblue tetrazolium reagents (Carl Roth & Co., Karlsruhe, Germany).

Trypan Blue Staining

Cell death was determined by trypan blue exclusion. After treatment with siRNA duplex or control oligonucleotides 100 μl of a 0.4% solution of trypan blue (Invitrogen) were added to 0.5 ml of a PC-3 cell suspension (1–2 × 10⁵ cells). After 10 to 15 minutes of incubation the suspension was applied to a hemocytometer. Both viable and nonviable cells were counted and the percentage of cell death was determined by counting trypan-blue-positive cells from three independent experiments.

In Situ End-Labeling (ISEL) and DAPI Staining

PC-3 cells (10⁵ cells/ml) were cytocentrifuged on glass slides, dried, fixed in acetone, and incubated with TBS containing 10% FCS and 0.3% H₂O₂ to block endogenous peroxidase activity. Cells were incubated for 60 minutes at 37°C with 50 μl of the labeling mix (250 U/ml terminal transferase, 20 μl/ml Dig-DNA labeling mix at 10X concentration, and 1 mmol/L CoCl₂) in reaction buffer for terminal transferase (Roche, Mannheim, Germany). Labeled DNA nicks were detected with a rabbit horseradish peroxidase (HRP)-conjugated F(ab)₂ fragment against digoxigenin (Dako, Hamburg, Germany) at a working dilution of 1:200. Incubation with 3,3′-Diaminobenzidin revealed brown nuclear signals. Controls were stained as above, omitting terminal transferase. As positive controls, lymph nodes with reactive follicular hyperplasia were used. Positive-stained cells were counted under a microscope (BX60; Olympus Optical Co. LTD, Japan) at a magnification of ×100 in five different fields using the analySIS software (Soft Imaging System GmbH, Munster, Germany).

For DAPI staining PC-3, LNCaP, and DU-145 cells (10⁵ cells/ml) were cytocentrifuged on glass slides, dried overnight, and fixed for 10 minutes in 100% acetone. Thereafter, cells were incubated with VECTASHIELD Mounting Medium with DAPI (Vector Laboratories Ltd., Peterborough, England). Stained cells were analyzed and counted under a fluorescent microscope (BX60; Olympus Optical Co., LTD) at a magnification of ×200 in five different fields using the analySIS software (Soft Imaging System GmbH).

Immunocytochemistry

Cytocentrifugated PC-3 cells (10⁵ cells/ml) were dried, fixed in acetone, and incubated with the polyclonal rabbit anti-human antibody against the active caspase-3 (clone AF835, R&D Systems GmbH, Wiesbaden, Germany) followed by incubation with a biotinylated secondary antibody, alkaline phosphatase-conjugated streptavidin (Dako) and by visualization with Fast Red (Dako). Slides were counterstained with hemalaun. Positive cells showed a red cytoplasmic staining around the clearly demarcated nuclei. Controls were stained as above omitting the first or secondary antibody. As a positive control, sections with gout tophi were used, as previously described.¹³

Results and Discussion

Array and Northern Blot Analysis of BI-1 Expression in Prostate Carcinoma

To identify genes that are differentially expressed in normal prostate and prostate carcinoma tissues, total RNA from matched prostate and prostate carcinoma were isolated (case 01, pT3aN0). Total RNA prepared from these tissues was used to synthesize 32P-labeled cDNAs by reverse transcription, followed by hybridization to two identical Atlas Select Human Tumor Arrays from BD Sciences Clontech as described in Materials and Methods. This array contains immobilized cDNAs of differentially-expressed genes from five different human tumors: bladder, breast, liver, lung, and prostate carcinoma. In total, 46 known and unknown differentially-expressed genes were identified to be up- or down-regulated in prostate carcinoma. The known genes showing a differential expression pattern in prostate tumor samples included transcription factors, protooncogenes, and other proteins, eg, Krox 24, c-jun, spermidyne acetyltransferase, ribosomal proteins, clusterin, and prostate secretory protein 94 (data not shown). One of the genes show-
**Figure 1.** Up-regulation of BI-1 expression in prostate carcinoma (PCa) compared with the benign counterpart (P) from the same gland. Total RNAs were extracted from either prostate carcinoma (case 01, Gleason score 5, pT3aN0) or corresponding normal prostate tissue, reverse-transcribed into cDNA and used in both hybridization experiments described below. A: Representative BI-1 and β-actin hybridization signals obtained from two identical Atlas Select Human Tumor Arrays using 32P-labeled cDNAs as probes. B: Northern blot analysis on total RNA (5 µg each) from both prostate carcinoma (PCa) and matched normal prostate (P) from the same patient is shown which was carried out using a human BI-1 cDNA fragment as a hybridization probe. C: Northern blot on total RNA (5 µg each) from DU-145, LNCaP and PC-3 cells using the same BI-1 cDNA as a probe. For integrity and equality of the RNA Northern blots were rehybridized with a human β-actin cDNA probe. D: The mRNA signals were scanned using the phosphorimager Molecular Imager FX, and the difference in the expression pattern in prostate carcinoma as compared to the paired normal prostate is shown which was carried out using a human BI-1 cDNA fragment as a hybridization probe. E: Western blot analysis of BI-1 and β-actin expression levels in DU-145, LNCaP, and PC-3 cells using the same BI-1 cDNA as a probe. For integrity and equality of the RNA Northern blots were rehybridized with a human β-actin cDNA probe. The Western blot was stripped and re-probed with an α-tubulin antibody to check for equal loading (50 µg) of total protein.

**BI-1 Expression in Human Prostate Cancer, Stromal Cells, and Benign Prostate Hyperplasia**

To confirm BI-1 overexpression detected by array and Northern blot analyses on RNA from bulk tumor tissues, prostate cancer specimens were subjected to both laser-capture microdissection and quantitative RT-PCR analysis. Before quantitative RT-PCR, RNA samples isolated from matched normal prostate and prostate cancer epithelial cells were checked for RNA integrity and RNA amount by analyzing an RNA aliquot on the Agilent Pico LabChip (Figure 2A). Subsequently, BI-1 mRNA expression was analyzed by quantitative RT-PCR on RNAs (equal amounts) from LCM-derived samples from 17 radical prostatectomies from cancer patients which were prepared as described in Material and Methods. In 11 of 17 cases BI-1 expression was up-regulated (more than 2 times) up to 12-fold in LCM samples derived from tumorous areas as compared to the paired normal prostate tissues (Figure 2B). The quantitative RT-PCR analysis did not show a significant correlation with specific clinico-pathological features such as pathological and clinical stage (Figure 2B).
Of prostatectomies were analyzed as described in B (derived from LCM paired stromal tissue and epithelial tissue (tumor-free) compared to matched normal prostate tissues are shown. /H9252

Figure 2. BI-1 expression in prostate carcinoma (PCa) and stromal tissue. A: Before quantitative RT-PCR the amount and integrity of total RNAs derived from paired laser-captured microdissected (LCM) samples were analyzed on an Agilent Pico LabChip. The bands for 28s RNA and 18s RNA are indicated (M, Ambion RNA 6000 ladder; P, normal prostate; PCa, prostate carcinoma). B: BI-1 expression and clinicopathological features of the patients analyzed in the present study. Prescreened total RNAs isolated from LCM paired normal prostates and prostate tumors from seventeen radical prostatectomies were analyzed by two-step real-time RT-PCR for BI-1 expression relative to \(-\text{actin. Factors of up-regulation of BI-1 expression in tumor specimens as compared to matched normal prostate tissues are shown. }^{*} \text{indicates factor} \quad \text{of up-regulation of BI-1 expression in comparison to tumor-free tissue normalized against} \quad \text{actin.} \quad \text{Bi} \quad \text{expression in stromal tissues. Total RNAs derived from LCM paired stromal tissue and epithelial tissue (tumor-free) from five radical prostatectomies were analyzed as described in B} \quad \text{indicates factor of down-regulation of BI-1 expression in stromal tissue in comparison to tumor-free tissue normalized against} \quad \text{actin.} \quad \text{Quantitative RT-PCR analysis on isolated RNA of five LCM-derived stromal tissue samples from radical prostatectomies showed a reduced BI-1 expression as compared to corresponding tumor-free epithelia (Figure 2C). Moreover, BI-1 expression was analyzed in five cases of benign prostatic hyperplasia (BPH) tissue samples from transurethral resections by using quantitative RT-PCR. Because no corresponding normal tissue was available to which we could relate BI-1, we calculated BI-1 expression absolutely as attomoles per pg total cellular RNA. In these five cases of BPH, BI-1 expression was determined with an average value of 1.1 attomoles per pg RNA. Compared to tumor-free epithelia from radical prostatectomies there seems to be a lower expression of BI-1 in BPH; however, this difference is without statistical significance \(n = 5; P = 0.31. \quad \text{Figure 3, C and D). It is worth mentioning that several Expressed Sequence Tag (EST) clones for BI-1 which are expressed in activated T-cells, Jurkat T-cells, and T-cell lymphomas can be identified in the National Center for Biotechnology Information EST database (Accession numbers: AA352408, AA354085, AA361535, respectively). Additionally, BI-1 expression was also found to be up-regulated in nucleophosmin-anaplastic lymphoma kinase-positive large cell lymphoma.}\ 17

Taken together, the expression studies clearly demonstrate that BI-1 expression is up-regulated in most cases of prostate cancer specimens (cells of epithelial origin) as compared to normal prostate epithelia and BPH. Furthermore, BI-1 expression in the prostate is mainly restricted to cells of the epithelial compartment, whereas stromal cells express only low BI-1 mRNA levels. However, due to the failure to detect BI-1 protein expression by using two different BI-1-specific antibodies on prostate cancer tissue sections (data not shown), lack of protein data could be a potential important shortcoming of this study.

Down-Regulation of BI-1 Expression Leads to Prostate Cancer Cell Death

RNA interference (RNAi) or RNA silencing is the process whereby double-stranded RNA (dsRNA or duplex RNA) induces the homology-dependent and specific degradation of cognate mRNA. The specific knockdown of expression of several genes was studied in a wide variety of species, such as Caenorhabditis elegans, Drosophila melanogaster, Arabidopsis thaliana, Neurospora crassa, and embryonic cells from mus musculus. \(^{18}\) More recently, the use of RNAi has been extended to differentiated mammalian cells. \(^{19,20}\) To evaluate the function of BI-1 in human PC-3, LNCaP, and DU-145 prostate carcinoma cells this novel approach of gene silencing through RNAi was applied. Transfection of PC-3, LNCaP, and DU-145 cells was accomplished with BI-1 sequence-specific siRNA duplex oligonucleotides. As negative controls single-strand sense and antisense RNA oligonucleotides against the BI-1 gene were used, as well as duplex siRNA oligonucleotides against the firefly luciferase gene (Pho\- tinus pyralis) and the human Mat-8 gene.

At different time points after transfection (24 hours, 36 hours, and 45 hours for PC-3 cells) or 45 hours after transfection (LNCaP and DU-145 cells), both prostate cancer cells attached to the bottom and cells floating in the medium were collected and used for the determination of down-regulation of BI-1 expression. To test whether transfection of PC-3 cells with BI-1 duplex siRNA could affect the expression of endogenous BI-1 mRNA, we analyzed RNA from duplex siRNA-transfected PC-3, LNCaP, and DU-145 cells with RNA from prostate cancer cells transfected with control oligonucleotides by Northern blot hybridization. We found that the expression of BI-1 in duplex siRNA-transfected (D-BI-1) prostate cancer cells was reduced by 50% to 70% relative to the control-transfected (control) cells (Figure 4, A and B). The same membranes were rehybridized with a cDNA probe...
for human β-actin to verify the integrity and amount of RNA in the samples (Figure 4, A and B). To investigate the knockdown of BI-1 expression in BI-1 duplex siRNA-transfected PC-3, LNCaP, and DU-145 cells at the protein level, Western blot analysis using a polyclonal antibody against BI-1 was performed. As shown in Figure 4C, the expression of BI-1 (45 hours after transfection) was specifically reduced by the cognate duplex siRNA (D-BI-1), but not when control oligonucleotides were used. The expression of a non-targeted housekeeping gene, α-tubulin, was unaffected and the reduction in BI-1 protein was more than 50% to 80% complete as quantified by Western blotting.

To assess the effect of BI-1 suppression on viability of PC-3 cells, cell death was studied using four different methods: 1) trypan blue exclusion to detect cell death attributable to membrane damage, 2) analysis of induced caspase-3 activity, 3) in situ end-labeling (ISEL) staining to detect DNA fragmentation, and 4) DAPI staining to detect nuclear changes such as fragmentation and condensation. After treatment of PC-3 cells with duplex siRNA oligonucleotides against BI-1, trypan blue exclusion test was applied where both viable and nonviable cells were counted. The amount of PC-3 cell death was analyzed by comparing the number of trypan-blue-positive cells to the number of unstained cells from three independent experiments. As shown in Figure 6A, induction of PC-3 cell death by duplex siRNA (D-BI-1) oligonucleotides occurred 24 hours after transfection (13% positively-stained cells), increased at 36 hours after transfection (43% positively-stained cells) and peaked at 45 hours after treatment (59% positively-stained cells). In contrast, control-transfected PC-3 cells (control) showed no increase in cell death over the indicated time period, but remained at a constant level of 4% to 5% dead cells (Figure 6A). Next, we wanted to determine whether duplex siRNA oligonucleotides against BI-1 were capable of inducing caspase-3 activity and/or apoptosis in human PC-3 prostate carcinoma cells. Again, induction of caspase-3 activity and measurement of apoptosis were investigated over a period of 45 hours. As can be seen in Figure 5B, transfection of PC-3 cells with duplex siRNA oligonucleotides (D-BI-1) caused an increase in the activity of caspase-3-like protease in PC-3 cells. The caspase-3 activity appeared at 24 hours (10% caspase-3-positive cells) and reached its maximum at 45 hours after treatment (38% caspase-3-positive cells), whereas control-transfected PC-3 cells (control) showed only low levels (1% to 2%) of caspase-3 activity over the whole time period (Figure 5A and data not shown). Apoptosis in duplex siRNA (D-BI-1) and control-transfected (control) PC-3 cells was determined by both ISEL and DAPI staining at various time intervals, apoptotic cells being recognized either by brown staining of the nucleus or con-
densed and fragmented nuclei (Figure 5, D and F; Figure 6B). In duplex siRNA-treated PC-3 cells, the number of apoptotic cells started to increase 24 hours after transfection (10% to 15% apoptotic cells) and the number of apoptotic cells continued to rise at subsequent sampling points, up to 45 hours (up to 45% apoptotic cells). In control-transfected PC-3 cells (control) apoptotic cells were minimally observed (2% to 4% apoptotic cells) over the indicated time period (Figure 5, C and E; Figure 6B). Thus, kinetically, the activation of caspase-3 paralleled the induction of apoptosis in duplex siRNA-transfected PC-3 cells. Furthermore, the increase in DNA fragmentation was almost comparable to that of trypan blue positively-stained cells, which suggested that the cytotoxicity induced by duplex siRNA against BI-1 was attributable to both necrotic and apoptotic death. However, it cannot be ruled out that trypan blue staining of PC-3 cells was accomplished due to secondary necrotic cells which are known to be readily formed from apoptotic cells over time. This hypothesis is supported by the fact that only apoptotic cells were observed after DAPI staining of transfected PC-3 cells.
In agreement with our results in human PC-3, LNCaP, and DU-145 prostate carcinoma cells, it has been previously demonstrated that BI-1 protein inhibits Bax-induced apoptosis in mammalian cells and when ectopically expressed in yeast. In addition, more recent studies showed that antisense down-regulation of plant NtBI-1 expression in tobacco BY-2 cells induced accelerated cell death and that overexpression of two plant BI-1 homologues suppressed Bax-induced apoptosis in human 293 cells. Furthermore, it was shown that BI-1 contains six or seven predicted transmembrane domains and the localization of BI-1 was found to be similar to Bcl-2, exhibiting a nuclear envelope and endoplasmic reticulum (ER)-associated pattern. When overexpressed in human cells, an association of BI-1 with Bcl-2 and Bcl-X\_L was demonstrated by both chemical cross-linking and co-immunoprecipitation experiments. Moreover, BI-1 was isolated as one of the candidate suppressors of the tumor necrosis factor-related apoptosis-inducing ligand.

Among the various prostate cancer cell lines, recent studies demonstrated that PC-3 cells are more resistant to apoptosis than LNCaP cells. More recently, Li and co-workers reported that overexpression of Bcl-X\_L underlies the molecular basis for resistance to staurosporine-induced apoptosis in PC-3 cells. Furthermore, treatment of PC-3 and MCF-7 cells with 5’Bcl-X antisense oligonucleotides sensitized both cell lines to various chemotherapeutic agents and radiation and increased cell death at lower doses of these agents. Finally, it was also reported that recurrent prostate cancer tissue samples expressed higher levels of Bcl-X\_L than benign prostate tissue. In the present study, PC-3 cells also had the highest levels of BI-1 expression and the majority of clinical specimens (12 of 18) of prostate cancer exhibited increased expression of this gene compared to benign prostate samples and BPH. In addition, the finding that PC-3 cells were more sensitive to BI-1 duplex siRNA-induced cell death, suggests that BI-1 may play a role in the progression of prostate cancer and that cancers that express high levels of BI-1 may benefit from treatment with the duplex siRNA oligonucleotides.

Furthermore, it is a well-known fact that a potential connection exists between the close relative Bcl-2 and hormone-independent prostate cancer. Our results presented in this study and the previous results demonstrating in vitro binding of BI-1 with Bcl-X\_L and Bcl-2 indicate that down-regulation of BI-1 protein in prostate cancer cells could change the balance of BI-1/Bcl-X\_L/Bcl-2 and Bax proteins and consequently, the cell death pathway can be activated as a Bax-induced apoptotic event. On the other hand, up-regulated BI-1 and Bcl-X\_L expression in prostate cancer cells (and other cancers) could also lead to an imbalance of BI-1/Bcl-X\_L/Bcl-2 and Bax proteins, thus inhibiting programmed cell death. In view of the observations reported in this study and of the well-established role of BI-1 as a powerful antiapoptotic factor, further studies are now warranted to address the correlation between BI-1 expression and the various phases of prostate cancer. Additionally, it will be important to understand the details of the signaling pathway involved in BI-1-mediated antiapoptotic effects.

Figure 6. Induction of PC-3, LNCaP, and DU-145 apoptotic cell death by using siRNAs against the human BI-1 gene. PC-3 cells were transfected with 150 nmol/L duplex siRNA oligonucleotides (D-BI-1) for various time intervals as indicated. As negative controls, 150 nmol/L single-strand BI-1 sense and antisense oligonucleotides and 150 nmol/L duplex siRNA oligonucleotides against the firefly luciferase gene or against the Mat-8 gene were used for transfection experiments, respectively. A: After transfection, PC-3 cells attached to the bottom and cells floating in the medium were collected and the percentage of cell death was assessed by trypan blue staining as described in Materials and Methods. Data, means of three independent experiments (±SE). B: Activation of caspase-3 and induction of apoptotic cell death after transfection of PC-3, LNCaP, and DU-145 cells was analyzed as indicated above and as described in Materials and Methods. Bar graphs represent the percentage of positively-stained cells for caspase-3 (PC-3), ISEL (PC-3), and DAPI-stained apoptotic cells (PC-3, LNCaP, and DU-145) at various time points. Data, means of three independent experiments (±SE). The number of both caspase-3 positive cells and apoptotic cells was determined by counting labeled cells in five randomly chosen high-power fields (original magnification ×100 for caspase-3 and ISEL, and ×200 for DAPI-stained cells).

To further test if a specific inhibition of BI-1 expression in other prostate carcinoma cell lines could lead to programmed cell death, LNCaP and DU-145 cells were transfected with duplex siRNA oligonucleotides against the BI-1 gene or control oligonucleotides over the indicated time period (24 hours to 45 hours) and analyzed for cell death by DAPI staining. Again, after transfection with BI-1 duplex siRNA oligonucleotides (D-BI-1), apoptotic LNCaP and DU-145 cells were detected after DAPI staining (Figure 5, G and I), whereas LNCaP and DU-145 cell death was only observed at a basal level after transfection with control oligonucleotides (Figure 5, G and I). Comparable to duplex BI-1 siRNA-transfected PC-3 cells, both duplex BI-1 siRNA-transfected LNCaP and DU-145 cells showed an increase of apoptotic cells over the whole time period, however, at a reduced level (Figure 6B). Even 45 hours after transfection cell death reached only a maximum level of 18% for LNCaP cells and 15% for DU-145 cells.
regulating BI-1 overexpression in prostate cancer (and other cancers). On the basis of our results, we conclude that down-regulation of BI-1 expression using the novel RNAi technique could serve as an effective approach for the treatment of prostate cancer in the future.

Acknowledgments

We thank S. Zischkau, J. Held, and M. Kickstein for excellent technical assistance.

References